SCHEMBL7048664

SCHEMBL7048664

CCCCCS(=O)(=O)c1cccc(N2CCNCC2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 14/20 0.58
DRD2 P14416 5/20 0.48
HTR1A P08908 5/20 0.48
HTR2A P28223 5/20 0.48
HTR7 P34969 5/20 0.48
ADRB1 P08588 3/20 0.48
HTR3E A5X5Y0 1/20 0.48
HTR3B O95264 1/20 0.48
TP53 P04637 1/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48
THRB P10828 1/20 0.48
CYP2C9 P11712 1/20 0.48
HTR2C P28335 1/20 0.48
SLC6A4 P31645 1/20 0.48
CYP2C19 P33261 1/20 0.48
HTR2B P41595 1/20 0.48
HTT P42858 1/20 0.48
HTR3A P46098 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11361080 0.99 HTR6 (0.56) HTR6DRD2HTR1AHTR2AHTR7
SCHEMBL3848542 0.83 HTR6 (0.62) HTR6DRD2HTR1AHTR2AHTR7
SCHEMBL11364768 0.80 DRD2 (0.58) DRD2THRBDRD3
SCHEMBL3846907 0.79 HTR6 (0.60) HTR6DRD2HTR1AHTR2AHTR7
SCHEMBL3454087 0.78 HTR6 (0.70) HTR6DRD2HTR1AHTR2AHTR7
SCHEMBL12719397 0.75 HTR6 (0.70) HTR6DRD2HTR1AHTR2AHTR7
SCHEMBL7044821 0.74 HTR2C (0.48) HTR6DRD2HTR2CSLC6A4SIGMAR1
SCHEMBL3846903 0.74 HTR6 (0.65) HTR6DRD2HTR1AHTR2AHTR7
SCHEMBL2626629 0.74 HTR6 (0.65) HTR6DRD2HTR1AHTR2AHTR7
SCHEMBL3849278 0.74 HTR6 (0.65) HTR6DRD2HTR1AHTR2AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6825202-B2 CENTRAL NERVOUS SYSTEM DISORDERS; PSYCHOLOGICAL DISORDERS SYNTEX (U.S.A.) LLC 2004-11-30 US disclosed
US-20030069254-A1 New arylsulfonyl derivatives with 5-HT6 receptor affinity SYNTEX (U.S.A.) LLC 2003-04-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069254-A1 New arylsulfonyl derivatives with 5-HT6 receptor affinity HTR6, HTR1A, HTR4 HTR6 1/4885DRD2 31/4885HTR1A 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.